JPMorgan analyst Cory Kasimov noted that Alkermes Chairman and CEO Richard Pops reviewed the company's current commercial products and discussed the '3831 opportunity and the company's pipeline at the JP Morgan Healthcare Conference. Talking about the '3831 NDA submission that was announced in the fourth quarter, Pops said the company expects the application to be accepted "very soon" and stressed that doctors are excited about the efficacy profile for '3831 without the effect of weight gain, according to Kasimov. The analyst, who continues to believe the company's share price gives it little credit beyond the base business, reiterated his Overweight rating on Alkermes coming out of the event.